JAK2 and acquired polycythemia vera: Initial reports documented that 95% of PV pts carry the V617F mutation (exon 14) of the JAK2 gene, resulting in a diminished JH2 inhibitory effect on the adjacent JH1 kinase domain, thus keeping JAK2 in a constitutively active conformation (Chen and Mullally 2014).